Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMNXI1E)

• Drug Name: 2-tert-butylbenzene-1,4-diol Drug Info
• Synonyms: Tert-Butylhydroquinone; tert-Butylhydroquinone; 1948-33-0; TBHQ; 2-tert-Butylhydroquinone; T-BUTYLHYDROQUINONE; MTBHQ; t-Butyl hydroquinone; 2-tert-Butyl-1,4-benzenediol; 2-t-Butylhydroquinone; Mono-tert-butylhydroquinone; Sustane; Tenox TBHQ; tert-Butyl-1,4-benzenediol; Mono-tertiarybutylhydroquinone; Hydroquinone, tert-butyl-; Banox 20BA; 1,4-Benzenediol, 2-(1,1-dimethylethyl)-; tertiary-Butylhydroquinone; 2-(1,1-Dimethylethyl)-1,4-benzenediol; 2-tert-Butyl(1,4)hydroquinone; 2-(tert-butyl)benzene-1,4-diol
• Cross-matching ID:
  PubChem CID: 16043
  ChEBI ID: CHEMBL242080
  CAS Number: CAS 1948-33-0
  TTD Drug ID: D0DQ2G

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Glutathione metabolism	2.37	0.00e+0	43/57 (75.44%)	GCLM;GPX2;PGD;...
Metabolism of xenobiotics by cytochrome P450	2.22	0.00e+0	49/77 (63.64%)	AKR1C1;ALDH3A1;EPHX1;...
Ferroptosis	2.07	0.00e+0	36/41 (87.8%)	HMOX1;GCLM;SLC7A11;...
Folate biosynthesis	2.04	2.41e-3	23/26 (88.46%)	AKR1B10;AKR1C3;AKR1B1;...
Pentose and glucuronate interconversions	1.95	1.93e-3	17/34 (50%)	AKR1B10;UGDH;SORD;...
Drug metabolism	1.87	8.04e-3	78/151 (51.66%)	ALDH3A1;CES1;GSTA1;...
Ribosome biogenesis in eukaryotes	1.85	9.65e-3	52/108 (48.15%)	RPP40;RPP30;REXO5;...
Fructose and mannose metabolism	1.84	9.65e-3	30/33 (90.91%)	AKR1B10;SORD;AKR1B1;...
Arachidonic acid metabolism	1.83	8.57e-3	48/61 (78.69%)	AKR1C3;GPX2;CBR3;...
Pentose phosphate pathway	1.82	8.68e-3	25/30 (83.33%)	PGD;G6PD;TKT;...
Viral myocarditis	1.80	1.32e-2	53/60 (88.33%)	CYCS;HLA-DOB;SGCB;...
Tyrosine metabolism	1.75	1.93e-2	30/36 (83.33%)	ALDH3A1;MAOA;ADH7;...
Parkinson disease	1.72	2.45e-2	176/249 (70.68%)	UCHL1;CYCS;TUBB2A;...
Aminoacyl-tRNA biosynthesis	1.67	4.48e-2	15/66 (22.73%)	CARS2;NARS2;IARS2;...
Porphyrin and chlorophyll metabolism	1.67	4.63e-2	23/43 (53.49%)	HMOX1;FECH;ALAS2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow

Multiple myeloma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U266	CVCL_0566	Homo sapiens	0.125uM - 10uM	6H, 24H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.125uM - 100uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.125uM - 100uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.125uM - 100uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.125uM - 100uM	3H, 6H, 24H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.125uM - 100uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.125uM - 100uM	6H, 24H	Show ▼

Peripheral blood

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.125uM - 10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.125uM - 100uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.125uM - 100uM	6H, 24H	Show ▼